Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1651-1660 Newer>

Managed Care December 2004 Adler & Schukman	The Role of Managed Care In Patient Safety & Error Reduction Patient safety and medical errors have become the focus of increasing attention from the public, policymakers, and accreditation agencies. Managed care organizations clearly are important stakeholders in this issue.
Managed Care December 2004 John Carroll	Pfizer Touts Medicaid Data In Arguing That DM Works The pharmaceutical giant Pfizer says that its disease management program saved Florida $42 million, but a state watchdog group remains unconvinced.
Managed Care December 2004	Go West, Young Pharmacist The pharmacy profession continues to pay well, though where somebody practices has much to do with just how well, according to the 2004 Pharmacy Compensation Survey.
Managed Care December 2004	Number of Prescriptions Grows Faster Than Population With the rising costs of prescriptions and other issues relating to implementation of the new Medicare drug benefit, it is no wonder that policymakers are considering new approaches to addressing drug costs.
Managed Care December 2004 Thomas Morrow	Artificial Heart Buys Precious Time The recently approved artificial heart marks a technological advance, but the reality of cost is a matter that needs addressing by managed care.
The Motley Fool January 3, 2005 Rich Duprey	Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA.
The Motley Fool December 31, 2004 W.D. Crotty	HealthSouth's Payment Plan The health-care provider's stock is up on settlement news, but buyers should beware.
The Motley Fool December 31, 2004 Michael Jaffe	Given Imaging's Happy Pill A new diagnostic technology provides the next gold standard for endoscopy. Does Given Imaging test positive for investor satisfaction?
BusinessWeek January 10, 2005 Bruce Einhorn	Asia Is Stem Cell Central Singapore isn't the only country in the region trying to profit from the U.S. restrictions. Australia, China, India, Japan, and South Korea all see stem cell research as a way to get ahead in biotech.
BusinessWeek January 10, 2005 Mara Der Hovanesian	Barr: A No-Name Star More than $30 billion in patents will elapse by the end of 2007, which spells new potential for generics such as Barr Pharmaceuticals. With Barr's solid pipeline, the stock, at $46, is a bargain.
<Older 1651-1660 Newer> Return to current articles.